Abstracts tagged "Clinical Response"

Abstract Number: 011 • 2020 Pediatric Rheumatology Symposium
Chronic Non-bacterial Osteomyelitis (CNO): Correlation Between Clinical and Radiological Findings
Martina Capponi ¹, Denise Pires Marafon ², Flaminia Rivosecchi ¹, Manuela Pardeo², Fabrizio De Benedetti ² and Antonella Insalaco ², ¹IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, ²Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy
Background/Purpose: Due to the lack of widely accepted diagnostic criteria or disease biomarkers, chronic non-bacterial osteomyelitis (CNO) remains a diagnosis of exclusion. Whole-body MRI (WB-MRI) has…
Abstract Number: 144 • 2020 Pediatric Rheumatology Symposium
Failure of Methotrexate Monotherapy and Subsequent Response to Tumor Necrosis Factor Inhibitors in Pediatric Non-Infectious Uveitis
Ashley Cooper¹, Basak Can Ermerak ², Katie Keck ³ and Erin Stahl ¹, ¹Children's Mercy Kansas City, Kansas City, ²University Hospitals Cleveland Medical Center, Cleveland, ³Palmetto Health USC Medical Group, Columbia
Background/Purpose: Pediatric non-infectious uveitis is often treated with systemic immunomodulators in a step-wise fashion, with methotrexate (MTX) followed by tumor necrosis factor alpha inhibitors (TNFi)…
Abstract Number: L12 • 2019 ACR/ARP Annual Meeting
Safety and Efficacy of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate – CREDO1 Study
Evgeniy Nasonov ¹, Saeed Fatenejad ², Elena Korneva ³, Diana Krechikova ⁴, Alexey Maslyansky ⁵, Tatyana Plaksina ⁶, Marina Stanislav ⁷, Rumen Stoilov ⁸, Tamara Tyabut ⁹, Sergey Yakushin ¹⁰, Elena Zonova ¹¹ and Mark Genovese¹², ¹FSBSI "Scientific Research Institute of Rheumatology n.a. V.A. Nasonova", Moscow, Russia, ²SFC Medica, Charlotte, North Carolina, ³R-Pharm, Moscow, Russia, ⁴Non-governmental Healthcare Institution "Regional Clinical Hospital at Smolensk station of OJSC "Russian Railways, Smolensk, Russia, ⁵SBHI "North-West Federal Medical Research Center n.a. V.A.Almazov" of the Ministry of Healthcare of the Russian Federation, St-Petersburg, Russia, ⁶SBHI of Nizhny Novgorod Region "Nizhny Novgorod Regional Clinical Hospital n.a. P.A.Semashko", N.Novgorod, Russia, ⁷V.A. Nasonova Research Rheumatology Institute, Moscow, Russia, ⁸UMHAT St. Ivan Rilski, Clinic of Rheumatology, Sofia, Bulgaria, ⁹Belarusian Medical Academy of Postgraduate Education, City Clinical Hospital N1, Minsk, Belarus, ¹⁰Ryazan State Medical University, Ryazan, Russia, ¹¹Novosibirsk State Medical University, State Clinical Polyclinic 1, Novosibirsk, Russia, ¹²Stanford University, Stanford, CA
Background/Purpose: Olokizumab (OKZ) is a new humanized monoclonal antibody targeting IL-6 1, 2. Here we present the results of the first phase III study of…
Abstract Number: 46 • 2019 ACR/ARP Annual Meeting
Key Inflammatory Biomarkers at Baseline Are Associated with Filgotinib Response at Week 12 in Rheumatoid Arthritis Patients with Inadequate Response or Intolerance to Biologic DMARDs
Peter Taylor¹, Emon Elboudwarej ², Bryan Downie ³, Rachael Hawtin ², Jinfeng Liu ² and Amer M. Mirza ², ¹University of Oxford, Oxford, United Kingdom, ²Gilead Sciences, Inc., Foster City, CA, ³Gilead Sciences, Inc., Foster Citty, CA
Background/Purpose: Filgotinib (FIL), an oral, selective, Janus Kinase 1 (JAK1) inhibitor was effective in Phase 3 studies of active RA in patients (pts) with inadequate…
Abstract Number: 220 • 2019 ACR/ARP Annual Meeting
A Positive Response to Nonpharmacological Therapies in Patients with Fibromyalgia
Raveendhara Bannuru¹, Michelle Park ², Lori Lyn Price ³ and Chenchen Wang ⁴, ¹Tufts Medical Center, Boston, MA, ²Tufts University School of Medicine, Boston, MA, ³Tufts Medical Center, Tufts University, Boston, MA, ⁴Tufts Medical Center, Boston
Background/Purpose: Identifying the factors associated with response to nonpharmacological therapies in patients with fibromyalgia will help personalize treatments and provide information to improve the design…
Abstract Number: 473 • 2019 ACR/ARP Annual Meeting
RA Presents in Disease Patterns Impacting Treatment Response
Kathryne Marks¹, Dana Symons ², Cynthia Crowson ³, Pamela Sinicrope ⁴ and Kelly O'Neill ⁵, ¹Rosalind Franklin University of Medicine and Science, Gurnee, IL, ²Rheumatoid Patient Foundation, Inc., Rockford, MI, ³Mayo Clinic Rochester, Rochester, ⁴Mayo Clinic, Rochester, MN, ⁵Rheumatoid Patient Foundation, Inc., Winter Springs, FL
Background/Purpose: Despite significant research on rheumatoid arthritis (RA), disease courses have not been clearly described. Like systemic lupus erythematosus and multiple sclerosis, RA displays a…
Abstract Number: 480 • 2019 ACR/ARP Annual Meeting
Not Achieving Clinical Remission Predicts a Poor Health-Related Quality of Life in Rheumatoid Arthritis Patients: Results of a Latin American Real World Database
Rocío-V. Gamboa-Cárdenas¹, Manuel Ugarte-Gil ², Cristina Reátegui-S ³, Victor Pimentel-Quiroz ⁴, Mariela Medina ¹, Zoila Rodríguez-Bellido ¹, Samira Garcia-H ⁵, Paola Zeña-Huancas ¹, Luciana Gil ¹, Erika Noriega ¹, Francisco Zevallos-M ¹, José Alfaro-Lozano ¹, Risto Perich-Campos ¹, César-A Pastor-A ⁶ and Graciela Alarcón ⁷, ¹Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Lima, Peru, ²Universidad Científica del Sur, Lima, Lima, Peru, ³Hospital Nacional Guillermo Almenara Irigoyen, Lima, Lima, Peru, ⁴Hospital Nacional Guillermo Almenara Irigoyen - EsSalud, Lima, Lima, Peru, ⁵Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Lima, Peru, ⁶Universidad Nacional Mayor de San Marcos, Lima, Lima, Peru, ⁷University of Alabama at Birmingham, Birmingham
Background/Purpose: Uncontrolled Rheumatoid Arthritis (RA) leads to disability, damage, and poor health-related quality of life (HRQoL). Current treatment recommendations emphasize the importance of achieving remission…
Abstract Number: 521 • 2019 ACR/ARP Annual Meeting
Discontinuation of Disease Modifying Drugs Due to Inefficacy in Patients with Incident Rheumatoid Arthritis
Zulema Rosales Rosado¹, pia Lois ¹, Arkaitz Mucientes Ruiz ¹, Esperanza Pato Cour ¹, Dalifer Freites Nuñez ², Juan Angel Jover Jover ¹, lydia Abasolo Alcazar ¹ and Leticia León ³, ¹HOSPITAL CLINICO SAN CARLOS, MADRID, Spain, ²Hospital Clínico San Carlos, MADRID, Spain, ³Fundación para la Investigación Biomedica, Madrid, Madrid, Spain
Background/Purpose: The treatment of Rheumatoid Arthritis (RA) has undergone a big change in the last two decades with the Disease Modifying Drugs (DMARDs). These drugs…
Abstract Number: 581 • 2019 ACR/ARP Annual Meeting
Allograft Inflammatory factor-1 Drives Th17 Like Pathologic Signature and Predict Poor Response to TNF Inhibitor in Ankylosing Spondylitis
Jeong Seok Lee¹, Eunyoung Lee ², Ji Yong Choi ³, Yeong-Wook Song ⁴, Eui-Cheol Shin ¹ and Eun Young Lee ², ¹Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Seoul, Republic of Korea, ³Seoul National University College of Medicine, Seoul, Republic of Korea, ⁴Seoul National University Hospital, Seoul, Republic of Korea
Background/Purpose: Ankylosing spondylitis (AS) is an inflammatory disease that commonly treated with TNF inhibitors for controlling active inflammation. To predict treatment response to TNF inhibitors…
Abstract Number: 1812 • 2019 ACR/ARP Annual Meeting
Delineating Early Response Trajectories to Biologics in Polyarticular Course Juvenile Idiopathic Arthritis
Lily SH Lim¹, Armend Lokku ², Sarah Ringold ³ and Eleanor M. Pullenayegum ⁴, ¹University of Manitoba, Winnipeg, MB, Canada, ²University of Toronto, TOronto, ON, Canada, ³Seattle Children's, Seattle, ⁴Child Health Evaluative Sciences, The Hospital for Sick Children, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
Background/Purpose: Most biologic trials in juvenile idiopathic arthritis (JIA) treat all participants with the biologic under study for 12 to 16 weeks before randomizing responders…
Abstract Number: 2354 • 2019 ACR/ARP Annual Meeting
Replication of a Prognostic Multivariable Prediction Model for Insufficient Clinical Response to Methotrexate in Early Rheumatoid Arthritis
Helen Gosselt¹, Maxime Verhoeven ², Maurits de Rotte ³, Saskia Pluijm ⁴, Gerrit Jansen ⁵, Janneke Tekstra ², Sandra Heil ⁶, Floris Lafeber ², Mieke Hazes* ⁷ and Robert de Jonge* ⁸, ¹Amsterdam UMC, VU Medical Center, Department of Clinical Chemistry, Amsterdam, The Netherlands and Erasmus MC, University Medical Center Rotterdam, Department of Clinical Chemistry, Rotterdam, The Netherlands, Amsterdam, Netherlands, ²UMC Utrecht, Department of Rheumatology & Clinical Immunology, Utrecht, The Netherlands, Utrecht, Netherlands, ³Amsterdam UMC, Amsterdam Medical Center, Department of Clinical Chemistry, Amsterdam, The Netherlands, Amsterdam, Netherlands, ⁴Prinses Máxima Centre for Paediatric Oncology, Department of Paediatric Oncology Utrecht, The Netherlands, Utrecht, Netherlands, ⁵Amsterdam UMC, VU Medical Center, Amsterdam Rheumatology and immunology Center, Amsterdam, The Netherlands, Amsterdam, Netherlands, ⁶Erasmus MC, University Medical Center Rotterdam, Department of Clinical Chemistry, Rotterdam, The Netherlands, Rotterdam, Netherlands, ⁷Erasmus MC, University Medical Center Rotterdam, Department of Rheumatology, Rotterdam, The Netherlands, Rotterdam, Netherlands, ⁸Amsterdam UMC, VU Medical Center, Department of Clinical Chemistry, Amsterdam, The Netherlands, Amsterdam, Netherlands
Background/Purpose: Methotrexate (MTX) constitutes first-line therapy in rheumatoid arthritis (RA). However, up to 40% of RA patients do not benefit from MTX therapy. To restrain…
Abstract Number: 2370 • 2019 ACR/ARP Annual Meeting
Discontinuation of Disease Modifying Drugs in Patients with Incident Rheumatoid Arthritis
pia Lois¹, Zulema Rosales Rosado ¹, Judit Font Urgelles ², Cristina Vadillo Font ¹, isabel Hernandez Rodriguez ¹, Juan Angel Jover Jover ¹ and lydia Abasolo Alcazar ¹, ¹HOSPITAL CLINICO SAN CARLOS, MADRID, Spain, ²HOSPITAL CLINICO SAN CARLOS, MADRID, Madrid, Spain
Background/Purpose: Treatment of Rheumatoid Arthritis (RA) has undergone a big change in the last two decades in strategies, objectives and therapeutic options, especially with the…
Abstract Number: 2599 • 2018 ACR/ARHP Annual Meeting
The Agreement between TNFi Treatment Responses and Fatigue Responses Is Weak to Moderate Suggesting Heterogeneity between Experienced Fatigue and Joint Inflammation: A Danish Population-Based Cohort Study
Tanja Schjødt Jørgensen¹, Marie Skougaard¹, Rebekka L Hansen¹, Christine Ballegaard¹, Philip J. Mease², Vibeke Strand³, Lene Dreyer⁴ and Lars Erik Kristensen¹, ¹The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen F, Denmark, ²Swedish Medical Center and University of Washington, Seattle, WA, ³Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ⁴Departments of Rheumatology and Clinical Medicine, Aalborg University Hospital and Aalborg University., Hellerup, Denmark
Background/Purpose: Despite better control of inflammation, e.g. with biological treatments, some patients with psoriatic arthritic (PsA) continue to cite fatigue as one of the most…
Abstract Number: 2627 • 2018 ACR/ARHP Annual Meeting
Not All Clinical Responders in SLE Are Equal: Comparison of Subcutaneous Belimumab + Standard of Care Responders to Placebo + Standard of Care Responders
William Stohl¹, Milena Kurtinecz², Joe Eastman³, Vanessa Castellano⁴, Chrysa Mahoney⁴, Tania Gonzalez-Rivera² and Bonnie Pobiner⁴, ¹Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ²GlaxoSmithKline, Philadelphia, PA, ³GlaxoSmithKline (at the time of the study), Research Triangle Park, NC, ⁴GlaxoSmithKline, Research Triangle Park, NC
Background/Purpose: To determine whether degree of response among responders to subcutaneous (SC) belimumab (BEL) + standard of care (SoC) is greater than that for responders…
Abstract Number: 581 • 2018 ACR/ARHP Annual Meeting
Comparative Analysis of Outcomes Among Patients with Rheumatoid Arthritis Initiating Tofacitinib in Combination with Oral MTX Who Discontinue, Interrupt, or Persist with MTX
Stanley Cohen¹, Boulos Haraoui², Jeffrey R. Curtis³, Timothy Smith⁴, John Woolcott⁵, David Gruben⁶, Christopher W Murray⁵, Noriko Iikuni⁴, Andrew Koenig⁵ and James Harnett⁴, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Institut de Rhumatologie de Montreal, Montreal, QC, Canada, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA, in combination with MTX or other non‑biologic (nb)DMARDs, or as monotherapy. Two…

1
2
3
…
7
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].